Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07471139) titled 'SWITCH: Apixaban vs Vitamin K in HM3' on Feb. 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Columbia University
Condition:
LVAD (Left Ventricular Assist Device) Thrombosis
Heart Failure
Bleeding
Thrombosis
Artery
Stroke
Heart Transplant
Intervention:
Drug: Warfarin
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: June 2026
Target Sample Size: 460
To know more, visit https://clinicaltrials.gov/study/NCT07471139
Published by HT Digital Conte...